Cryosite Limited (ASX:CTE) Insider Purchases A$830,000.00 in Stock

Posted by on May 2nd, 2024

Cryosite Limited (ASX:CTE – Get Free Report) insider Mark Kerr acquired 1,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were bought at an average cost of A$0.83 ($0.55) per share, for a total transaction of A$830,000.00 ($546,052.63).

Cryosite Stock Performance

The company has a quick ratio of 1.76, a current ratio of 2.32 and a debt-to-equity ratio of 87.26.

About Cryosite

(Get Free Report)

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological, as well as logistics services to the clinical trials, research, and pharmaceutical industries.

Featured Articles

Receive News & Ratings for Cryosite Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryosite and related companies with MarketBeat.com's FREE daily email newsletter.